SANTA MONICA, Calif. – GoodRx announced that it is working with Eli Lilly and Company to expand access to the newly FDA-approved oral GLP-1 medication, Foundayo (orforglipron). Eligible self-pay patients can access Foundayo through GoodRx at a starting price of $149 per month, in line with the lowest available discounted cash price at launch. The offering provides transparent pricing and nationwide pharmacy access for the highly anticipated weight management treatment.
GoodRx is also expanding access to Zepbound (tirzepatide) KwikPen, available to eligible self-pay patients starting at $299 per month at more than 70,000 pharmacies nationwide. Together with the launch of Foundayo, these offerings expand access to both oral and injectable GLP-1 treatments for adults seeking prescribed obesity care outside traditional insurance pathways.
“We’re excited to work with Lilly to help bring one of the most anticipated innovations in weight management to patients,” said Wendy Barnes, President and CEO of GoodRx. “As new GLP-1 therapies continue to expand, including oral options like Foundayo, it is critical that access evolves alongside innovation. By pairing transparent cash pricing with nationwide pharmacy access and integrated care, we are helping ensure more people understand their options and more easily start treatment.”
“The launch of Foundayo reflects Lilly’s continued commitment to expanding treatment options for people living with obesity and advancing meaningful innovation in this category,” said Laura Steele, Group Vice President of U.S. Cardiometabolic Health at Eli Lilly and Company. “We're committed to expanding access to treatment options through channels that meet patients where they are in their journey.”
Supporting New Access Models for Drug Launches
GoodRx’s role in expanding access to Foundayo reflects a broader shift in how innovative therapies reach patients. For many medications, particularly GLP-1 treatments prescribed for weight loss, insurance coverage remains inconsistent or unavailable, prompting manufacturers to explore new direct-to-consumer access models. GoodRx supports this shift by combining transparent discounted cash pricing, nationwide pharmacy access, and a trusted consumer platform that helps patients start treatment while maintaining continuity of care and the ability to fill prescriptions at their pharmacy of choice.
Submit Your Press Release
Have news to share? Send us your press releases and announcements.
Send Press Release
